Dr. Takeshi Yoshimoto - Cancer - Best Researcher Award

University of Tsukuba Hospital - Japan

Author Profile

🎓 Early academic pursuits

Dr. Takeshi Yoshimoto began his academic journey in the medical sciences with a strong foundation in clinical education. he earned his m.d. from hiroshima university faculty of medicine in march 2008, followed by a ph.d. from the graduate school of biomedical and health sciences, hiroshima university in august 2022. during his formative years, his curiosity about cerebrovascular diseases led him to explore genetics, biomarkers, and translational medicine, laying the groundwork for his future research focus, which indirectly intersects with diagnostic technologies resembling the precision systems used in power electronics.

🧠 Professional endeavors

Dr. Yoshimoto's career showcases a rich progression through esteemed institutions. from his early role as an intern at fukushima coop hospital, he gradually ascended through ranks at national cerebral and cardiovascular center, serving as resident, senior resident, Cancer and later as a medical doctor under distinguished mentors like dr. ihara and dr. toyoda. he also contributed to academia at hiroshima university and currently serves as a lecturer in the department of stroke and cerebrovascular diseases at university of tsukuba hospital. his consistent clinical involvement paired with academic appointments underlines his dual commitment to patient care and neurological research.

🧬 Contributions and research focus

A pioneer in translational stroke research, dr. yoshimoto focuses on integrating genetics with acute stroke management. his primary research involves developing algorithms for selecting clot removal devices by identifying genetic variations, particularly the moyamoya-related rnf213 p.r4810k polymorphism. he explores the association between juvenile strokes and serum biomarkers. his projects are comparable in Cancer precision and application-oriented design to power electronics, highlighting his innovative integration of medical diagnostics and genetic profiling to improve acute care strategies.

🌍 Impact and influence

Dr. Yoshimoto’s work has had significant impact on cerebrovascular research, especially in japan. his dedication to exploring the genetic underpinnings of stroke has advanced understanding of moyamoya disease and enhanced patient stratification for endovascular therapy. his influence is also evident in the repeated recognition he received at prestigious national and international conferences, positioning him as a leading voice Cancer in neurovascular translational research. the framework he established for genetic-based intervention selection has potential parallels with feedback and adaptive systems in power electronics, reflecting the precision and personalization he brings to neurology.

🏆 Academic cites and recognition

Dr. Yoshimoto’s excellence has been widely acknowledged. he received the paul dudley white international scholar award from the american heart association in 2021 and multiple presentation awards at the japan stroke society and japanese society of neuroendovascular therapy (jsnet). notably, he received teaching awards and outstanding paper honors, reinforcing his role Cancer as both a scholar and mentor. these accolades validate the academic rigor and practical relevance of his work, particularly his contributions to stroke genetics and device selection.

🔬 Legacy and future contributions

Dr. Yoshimoto is poised to continue shaping the future of stroke research with a strong emphasis on personalized medicine. he aims to refine and implement his clot removal device selection algorithm into broader clinical practice. further integration of genetic biomarkers into real-time therapeutic decision-making is expected. his work not only improves outcomes for stroke patients but also sets a model for interdisciplinary research convergence, similar to how power electronics evolved by merging physics, control theory, and electrical engineering.

Notable Publication

Title: Relationship Between RNF213 p.R4810K and Echocardiographic Findings in Patients with Cerebrovascular Diseases: A Multicenter Prospective Cohort Study
Author(s): Kotaro Noda, Yorito Hattori, Tatsuya Nishii, Yoshikazu Nakaoka, Masafumi Ihara
Journal: Journal of the American Heart Association, 2025
Title: Deep learning-based post hoc denoising for 3D volume-rendered cardiac CT in mitral valve prolapse
Author(s): Tatsuya Nishii, Tomoro Morikawa, Hiroki Nakajima, Satsuki M. Fukushima, Tetsuya Fukuda
Journal: International Journal of Cardiovascular Imaging, 2025
Title: Evaluation of the Efficacy and Accuracy of Super-Flexible Three-Dimensional Heart Models of Congenital Heart Disease Made via Stereolithography Printing and Vacuum Casting: A Multicenter Clinical Trial
Author(s): Isao Shiraishi, Masaaki Yamagishi, Takaya Hoashi, Toshiaki Hisada, Kenichi Kurosaki
Journal: Journal of Cardiovascular Development and Disease, 2024
Title: Pericardial adhesion and performance of hemodynamically significant constrictive pericarditis using cine magnetic resonance feature tracking
Author(s): Yasutoshi Ohta, Midori Fukuyama, Yoshiaki Morita, Hiroki Horinouchi, Tetsuya Fukuda
Journal: International Journal of Cardiovascular Imaging, 2024
Title: Laterality of CT-measured hepatic extracellular volume fraction in patients with chronic thromboembolic pulmonary hypertension
Author(s): Tatsuya Nishii, Hiroki Horinouchi, Takara Namboku, Takeshi Ogo, Tetsuya Fukuda
Journal: International Journal of Cardiovascular Imaging, 2024
Title: Covering the intercostal artery branching of the Adamkiewicz artery during endovascular aortic repair increases the risk of spinal cord ischemia
Author(s): Yoshimasa Seike, Tatsuya Nishii, Kazufumi Yoshida, Tetsuya Fukuda, Hitoshi Matsuda
Journal: JTCVS Open, 2024

Early academic pursuits 🎓

Jerzy trojan completed his doctorate d’état ès sciences (hdr) at the prestigious sorbonne - p&m curie. during this formative period, he laid the groundwork for his future contributions to biomedical science, specifically in the field of cancerology. his early research endeavors, characterized by a rigorous scientific approach, focused on critical aspects of oncology and laid the foundation for his later groundbreaking work.

Professional endeavors 🏥

Jerzy has held various esteemed positions throughout his career, reflecting his commitment to advancing cancer research. he is currently a visiting professor at the insitm, cancer center, and paris-saclay university in villejuif, france, where he has been since 2019. before this, he served as president and research director at the international cancer gene therapy and oncology diagnostics center (ceadea) in bogota, colombia, and has also held prominent roles in institutions across the usa and europe, including case western reserve university and the sidney kimmel cancer center. these diverse experiences have equipped him with a comprehensive understanding of both the scientific and clinical aspects of cancer treatment.

Contributions and research focus 🔬

Dr. trojan is best known for establishing cancer gene therapy, particularly immuno-gene therapy, as a pivotal domain within oncology. his pioneering research, highlighted in publications from 1993, led to significant advancements in the treatment of glioblastoma, showcasing the therapeutic potential of gene therapy. Immuno - gene therapy additionally, he explored the intersection between neuro-ontogenesis and neuro-oncogenesis, identifying afp and igf-i as novel biomarkers, which have implications for understanding central nervous system differentiation and cancer progression.

Accolades and recognition 🏆

In recognition of his substantial contributions to biomedical science, jerzy was elected as a member of the prestigious french academy of medicine (anm) in paris in 2017. his extensive body of work includes nearly 370 publications, encompassing 140 articles, 102 book chapters, and four books, which have garnered over 3,500 Immuno - gene therapy citations. this impressive scholarly output underscores his impact and influence in the field of cancer research.

Impact and influence 🌍

Dr. trojan's research has significantly shaped the landscape of cancer therapy, particularly in immunotherapy. his establishment of immuno-gene therapy has opened new avenues for treating aggressive cancers, thus influencing both academic research and clinical practices. his work has not only contributed to theoretical Immuno - gene therapy advancements but has also informed practical applications that benefit patients facing challenging diagnoses.

Legacy and future contributions 🔮

With an enduring commitment to advancing cancer research, jerzy trojan continues to influence the field through his current role as a visiting professor and research director. his legacy is evident in the ongoing projects aimed at improving cancer treatment outcomes, particularly through innovative therapeutic strategies. as he continues to publish and mentor the next generation of researchers, his contributions will undoubtedly have a lasting impact on the future of oncology and gene therapy.

Notable Publications

Title: Precancerous Disease Systemic Lupus Erythematosus–The Role of BAFF in Corticosteroids Treatment
Author: J. Trojan et al.
Journal: Medical Research and Its Applications, Vol. 6, Pages 114-127
DOI: 10.9734/bpi/mria/v6/7520C
Publication Date: June 3, 2024

Title: Anti-Gene IGF-I Vaccines in Cancer Gene Therapy: A Review of a Case of Glioblastoma
Author: J. Trojan
Journal: Current Medicinal Chemistry, Vol. 31, Pages 1982-2002
DOI: 10.2174/0109298673231106095141
Publication Date: March 11, 2024

Title: Establishment of Cancer Gene Therapy
Author: J. Trojan
Journal: Cambridge Scholars Publishing
Publication Date: March 2, 2023

Title: Neoplastic brain, glioblastoma and immunotherapy
Author: J. Trojan et al.
Journal: In: Brain and Spinal Tumors - Primary and Secondary, Ed. L.R. Morgan, F.B. Sarica, InTechOpen
Publication Date: 2020

Title: In vitro technical aspects of Anti–Gene IGF-I vaccines against glioma
Author: J. Trojan et al.
Journal: IBR, Vol. 3(1), Pages 43-48
Publication Date: 2019